Seattle sees second indication for brentuximab BLA

Seattle Genetics Inc. (NASDAQ:SGEN) said it hopes to seek approval of brentuximab vedotin ( SGN-35) for anaplastic large cell lymphoma (ALCL) in its BLA submission planned for 1H11. The announcement came as Seattle Genetics and partner Millennium Pharmaceuticals Inc. reported top-line data from an international Phase II trial in 58 patients with relapsed or refractory ALCL that showed the compound produced an objective response rate of 86%. The median duration of response has not been reached at a median follow-up of about six months in the single-arm, open-label study. ...